Clinical Trial Update: Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial is assessing safety and immunogenicity of a recombinant varicella zoster vaccine in people with HIV across CD4 strata and a healthy control gro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Recombinant Varicella Zoster Virus Vaccine (recombinant varicella zoster virus vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Herpes Zoster | Phase 1, Phase 2 | Status: RECRUITING